Drug Manufacturers - General stocks
Every US Drug Manufacturers - General company with filed annual reports: 20, in the Healthcare sector, with the ratios the screener prints. A name opens the company’s page, where every filed figure carries the filing it was read from and every price the day of its close.
Medians across Drug Manufacturers - General companies
- Price to earnings
- 22.12x of 16
- Price to book
- 5.31x of 17
- Enterprise value to EBIT
- 19.95x of 14
- Free cash flow yield
- 5.4% of 17
- Return on invested capital, after tax
- 15.7% of 12
- Debt to equity
- 0.78 of 13
- Dividend yield
- 2.3% of 11
The companies
| Company | Market cap | P/E | P/B | EV/EBIT | FCF yld | ROIC | D/E | Div yld |
|---|---|---|---|---|---|---|---|---|
| Eli Lilly and Company LLY | 1.18T | 54.42x | 42.42x | 43.65x | 0.8% | 33.8% | 1.65 | 0.5% |
| Johnson & Johnson JNJ | 610.40B | 22.76x | 7.55x | 19.22x | 3.2% | 24.8% | 0.61 | 2.1% |
| AbbVie Inc. ABBV | 500.80B | 119.57x | n/m | 37.52x | 3.5% | 16.1% | n/m | 2.4% |
| Merck & Co., Inc. MRK | 358.60B | 19.91x | 6.93x | 17.85x | 3.4% | 21.9% | 0.96 | 2.3% |
| Novartis AG NVS | 285.80B | 20.44x | 6.20x | 17.29x | 6.2% | 23.1% | 0.66 | n/a |
| AstraZeneca PLC AZN | 258.50B | 25.28x | 5.31x | 20.68x | 4.5% | 15.2% | 0.65 | 1.9% |
| Amgen Inc. AMGN | 234.70B | 30.29x | 27.17x | 31.01x | 3.4% | 14.2% | 6.40 | 2.3% |
| Gilead Sciences, Inc. GILD | 195.10B | 23.01x | 8.70x | 21.50x | 4.8% | 21.4% | 1.13 | 2.1% |
| Novo Nordisk A/S NVO | 174.40B | 11.35x | 5.99x | n/a | 5.1% | n/a | n/a | 4.5% |
| Pfizer Inc. PFE | 167.80B | 21.49x | 1.94x | 23.01x | 5.4% | n/a | 0.78 | 5.8% |
| Bristol-Myers Squibb Company BMY | 123.70B | 17.46x | 6.69x | 14.30x | 10.4% | 15.3% | 2.55 | 4.2% |
| Sanofi SNY | 98.69B | 11.26x | 1.23x | 15.89x | 8.2% | n/a | 0.29 | n/a |
| GSK plc GSK | 98.21B | 12.95x | 4.52x | n/a | 8.6% | n/a | n/a | n/a |
| Biogen Inc. BIIB | 34.77B | 26.65x | 1.90x | 20.98x | 5.9% | 6.9% | 0.36 | n/a |
| Grifols, S.A. GRFS | 6.38B | 36.25x | 0.97x | 7.14x | 11.8% | 6.6% | 0.65 | n/a |
| Organon & Co. OGN | 3.61B | 19.11x | 4.77x | 12.72x | 15.0% | 4.5% | 11.70 | 0.6% |
| Citius Oncology, Inc. CTOR | 69.4M | n/m | 1.22x | n/a | n/a | n/a | n/a | n/a |
| MIRA Pharmaceuticals, Inc. MIRA | 27.6M | n/m | 2.66x | n/a | n/a | n/a | n/a | n/a |
| Scilex Holding Company SCLX | 19.8M | n/m | n/m | n/a | 18.6% | n/a | n/m | n/a |
| SRx Health Solutions Inc. SRXH | 12.3M | n/m | n/a | n/a | n/m | n/m | n/m | n/a |
Largest published market value first. No ratio orders this list, and a company whose market value is not published is listed last.
Prices as of 2026-10-15. Ratios recomputed from the filings 2026-10-15. Every ratio passes the same applicability gate as the screener and the research page, with the latest filed fiscal year's statements. A list is not a recommendation: see the limits of what this tool can tell you.